Vimy Pharmaceuticals raised C$14.5 million at C$3.00 a share this fall. It reports no revenue. On November 17 its co-founders opened the market at the Toronto Stock Exchange to mark the company’s first day on the TSX Venture Exchange, while its generic version of Ozempic waits in Health Canada’s review queue.
Vimy Pharmaceuticals Lists on TSXV After Harmony Reverse Takeover
Vimy Pharmaceuticals Corp. (TSXV: VIMY) reached the public market through a reverse takeover, a deal in which a private company merges into an already-listed entity and its owners end up in control. The listed entity was Harmony Acquisitions Corp., a capital pool company: a TSXV-listed shell with no operating business, formed to find and complete one acquisition, called its Qualifying Transaction. Vimy closed that transaction on November 12 through a three-cornered amalgamation under Ontario law.
The share mechanics took two steps. Harmony consolidated its stock at one new share for every 49.6104 old shares and renamed itself Vimy Pharmaceuticals Corp., and each share of the private Vimy, after a 34-for-one split, was swapped for one share of the listed company. That left 32,347,829 shares outstanding. The stock trades as a TSXV Tier 2 issuer.
Harmony and Vimy announced a non-binding letter of intent on August 6. Harmony announced the TSXV’s conditional approval on November 6, and CEO David Suchon and his two co-founders opened the market in Toronto on November 17 to mark the first day of trading.
Vimy’s releases describe a management team that includes former executives of Novo Nordisk (NYSE: NVO) (Nasdaq Copenhagen: NOVO B), the maker of brand-name Ozempic. They give no individual biographies.
The shares trade only on the TSXV. No US over-the-counter quotation was identified in the sources reviewed, so US investors should confirm with their broker whether the stock can be bought and whether it is DTC eligible, meaning the Depository Trust Company can clear and settle it through standard US brokerage accounts.
Vimy’s Generic Ozempic Filing Is Under Review, Not Approved
An Abbreviated New Drug Submission, or ANDS, is the filing a company makes to Health Canada to show that its generic product matches a drug already on the market. Vimy said in May that it had filed its ANDS for a generic Ozempic earlier that month. Its November releases add that Health Canada found the submission acceptable for review.
That is a screening step. It is not an approval. Neither Vimy nor Health Canada has published a decision date, and neither of Vimy’s semaglutide products is authorized for sale in Canada. A second ANDS, for a generic version of the weight-management drug Wegovy, has also been filed; the company gives no review status for it.
Vimy would not be first to market. Health Canada authorized its first generic semaglutide on April 28, a version of Ozempic from Dr. Reddy’s Laboratories (NYSE: RDY) (NSE: DRREDDY), and said at the time it was reviewing eight other submissions. By June 29 the regulator had approved its third generic semaglutide product, Sevmia from privately held Apotex, with six submissions still under review. Sandoz Canada, part of Sandoz Group AG (SIX: SDZ) (OTCQX: SDZNY), announced authorization for its own generic Ozempic on September 18.
On manufacturing, the company says development was done in Canada and that commercial production will be domestic, with Canadian partners its November releases do not name. The May release pointed to a partnership with Applied Pharma’s Critical Medicines Production Centre in Edmonton, without terms or capacity figures. The market-size figure in Vimy’s materials, C$3.5 billion in 2025 Canadian semaglutide injection sales, up 31%, is attributed to a Globe and Mail article rather than to company data.
Vimy Pharmaceuticals’ C$14.5 Million Raise and Its Stated Uses
The money came in before the listing. Vimy sold 4,846,354 subscription receipts at C$3.00 each, in tranches that closed September 28 and October 22, for gross proceeds of C$14,539,062. A subscription receipt holds an investor’s cash in escrow and converts into shares only once a set event closes, in this case the go-public deal. Beacon Securities Limited led the agent syndicate.
Those financing shares make up about 15% of the current share count. The agents also received 249,194 compensation warrants exercisable at C$3.00 until November 12, 2028; the cash fee paid to them is not stated. Triforce Ventures SA, the finder on the deal, was paid in stock, taking 208,333 shares at a deemed C$3.00 against a C$625,000 fee, and 457,306 immediately vesting options were granted at the same price.
According to the November 12 release, the proceeds are earmarked for research and development of new generics, including the semaglutide program, and for entry into international markets. Direct-to-consumer advertising and building out the VimyDirect online pharmacy are also on the list, along with Canadian manufacturing and technology transfer, regulatory and commercialization work, transaction costs and working capital.
No specific cash runway or burn rate was identified in the sources reviewed. At the C$3.00 financing price, the 32,347,829 shares work out to about C$97 million; that is arithmetic on the placement price, not a market quote. Vimy has also engaged Independent Trading Group (ITG), Inc. as market maker for C$7,000 a month, subject to TSXV approval.
Who Controls Vimy Pharmaceuticals After the Listing
Three holders own most of the company. K2 Principal Fund L.P. reported 7,990,642 shares, about 24.70%, in an early warning report filed November 13; Canadian rules require that disclosure once a holder crosses 10%. Suchon holds 6,344,684 shares, about 19.61%, and Smith holds 5,643,400, about 17.45%, according to the November 12 release. Combined, that is roughly 61.8%.
K2’s filing puts its average cost at about C$0.7391 a share. Of its position, 500,000 shares came from subscription receipts bought at the same C$3.00 other investors paid, and the remaining 7,490,642 came from its earlier stake in the private company. While it holds at least 10%, K2 can nominate one director; its initial nominee is Riccardo Trecroce, who sits on the six-member board.
Escrow, a TSXV requirement for principals in a deal like this, locks shares up and releases them on a fixed schedule. Vimy’s escrow agreement covers 22,535,642 shares, about 70% of the total. Ten percent is released on the date of the TSXV’s final acceptance bulletin, with 15% due at each of 6, 12, 18, 24, 30 and 36 months after that. Most of the stock cannot trade yet.
Vimy Pharmaceuticals Escrow Schedule and Health Canada Timing
The first 15% release of Vimy’s escrowed shares falls six months after the TSXV’s final acceptance bulletin, with further 15% tranches every six months through month 36. K2’s shares carry contractual transfer restrictions of up to 12 months from the November 12 closing. The 249,194 agent compensation warrants expire on November 12, 2028. Neither Vimy nor Health Canada has published a decision date for the generic Ozempic or generic Wegovy submission.
Sources
- TMX Group / Newsfile: Vimy Pharmaceuticals Corp. (TSXV: VIMY) Opens the Market, November 17, 2026
- Newsfile (full text via FinanzNachrichten): Vimy Pharma Completes Qualifying Transaction, November 12, 2026
- Newsfile (full text via Stockhouse): Harmony Receives TSXV Conditional Approval & Files Filing Statement Regarding Qualifying Transaction with Vimy Pharma, November 6, 2026
- Newsfile (full text via TMX Money): Vimy Pharmaceuticals Announces Closing of Second Tranche of Brokered Private Placement for Aggregate Proceeds of $14.5 Million; Shareholder Approval for Go-Public Transaction, October 22, 2026
- Newsfile: Harmony Acquisitions Announces Proposed Qualifying Transaction with Vimy Pharmaceuticals, August 6, 2026
- Newswire.ca (CNW): The K2 Principal Fund L.P. Updated Holdings in Vimy Pharmaceuticals Corp., November 13, 2026
- Newswire.ca (CNW): Vimy Pharma Files Health Canada Submission for Generic Ozempic (Semaglutide), May 28, 2026
- Health Canada: Canada becomes the first G7 country to approve a generic version of semaglutide, April 28, 2026
- Health Canada: Canada approves first generic semaglutide for weight loss, June 29, 2026
- Newswire.ca (CNW): Sandoz Canada receives Health Canada regulatory approval for Sandoz Semaglutide, a generic version of Ozempic, September 18, 2026
Editorial Disclosure
This article is based entirely on publicly available information, including company press releases, an early warning report and Health Canada announcements. The security discussed is Vimy Pharmaceuticals Corp. (TSXV: VIMY), formerly Harmony Acquisitions Corp. (TSXV: MONY.P). Other securities referenced are Novo Nordisk A/S (NYSE: NVO) (Nasdaq Copenhagen: NOVO B), Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) (NSE: DRREDDY) and Sandoz Group AG (SIX: SDZ) (OTCQX: SDZNY). Apotex, K2 Principal Fund L.P., Beacon Securities Limited, Triforce Ventures SA, Independent Trading Group (ITG), Inc. and Applied Pharma’s Critical Medicines Production Centre are referenced as entities with no publicly listed security discussed here. aktiego.com has not received any compensation from Vimy Pharmaceuticals, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any of these securities at the time of publication.
Vimy became public through a reverse takeover of a capital pool company and reports no revenue in its November 2026 releases; no specific cash runway or burn rate was identified in the sources reviewed. Health Canada has found Vimy’s generic Ozempic submission acceptable for review, which is a screening step and not an approval; the generic Wegovy submission has no disclosed review status, neither product is authorized for sale, and no decision date has been published. At least four generic semaglutide products from other manufacturers had been authorized in Canada before Vimy listed. The C$3.5 billion market figure is a third-party estimate cited by the company. Its November releases do not name the Canadian partners for commercial manufacturing. The company’s own release states that trading in securities of a capital pool company should be considered highly speculative.
The C$14.5 million financing was priced at C$3.00 per subscription receipt and represents about 15% of the 32,347,829 shares outstanding. The 249,194 compensation warrants and 457,306 stock options are potential further dilution, and any future financing would add more. Three holders own roughly 61.8% of the shares, and about 70% of outstanding shares are subject to TSXV escrow with staged releases over 36 months, which may limit trading liquidity. K2 Principal Fund L.P. reports an average cost of about C$0.7391 per share across its position, including 500,000 shares bought at the same C$3.00 price as other financing participants. The C$97 million figure is arithmetic at the financing price, not a market capitalization. The shares are listed only on the TSXV, with no US OTC quotation identified; US investors should check with their broker on availability and DTC eligibility. The November 12, 2026 release was verified through a full-text reproduction carrying its original Newsfile dateline. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of the company’s press releases, per the company’s own standard disclosure.
Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER











